| Date |
Title |
|
|
04/07/21
|
Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer
|
|
|
03/25/21
|
Alkermes to Take Part in Stifel's 3rd Annual CNS Day
|
|
|
03/25/21
|
Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy
|
|
|
03/11/21
|
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
|
|
|
03/04/21
|
Alkermes to Hold Virtual Investor Day
|
|
|
02/18/21
|
Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference
|
|
|
02/11/21
|
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
|
|
|
02/04/21
|
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
|
|
|
01/14/21
|
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
|
|
|
01/06/21
|
Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
|
|
|
01/06/21
|
Alkermes Announces Updates to Executive Leadership Team
|
|
